Skip to main content
Subscribe
Log In
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest content
Current issue
Archive
Authors
Podcasts
About
Search for this keyword
Advanced search
Close
More
Main menu
Latest content
Current issue
Archive
Authors
Podcasts
About
Subscribe
Log in
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
You are here
Home
Archive
Volume 70, Issue 8
Corrections
Email alerts
Responses
Article menu
Article
Text
Article
info
Citation
Tools
Share
Rapid Responses
Article
metrics
Alerts
See original article:
Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies - February 01, 2009
Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis - January 01, 2009
Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade - June 01, 2009
Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study - July 01, 2009
Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe - April 01, 2009
Long-term efficacy and toxicity of ciclosporin A in combination with methotrexate in poor prognosis rheumatoid arthritis - May 01, 2009
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal - June 01, 2009
Diagnosing axial spondyloarthropathy. The new Assessment in SpondyloArthritis international Society criteria: MRI entering centre stage - June 01, 2009
Baseline and 1-year magnetic resonance imaging of the sacroiliac joint and lumbar spine in very early inflammatory back pain. Relationship between symptoms, HLA-B27 and disease extent and persistence - November 01, 2009
Adaptation and cross-cultural validation of the rheumatoid arthritis work instability scale (RA–WIS) - November 01, 2009
MRI and clinical findings in patients with ankylosing spondylitis eligible for anti-tumour necrosis factor therapy after a short course of etoricoxib - September 01, 2009
Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study - December 01, 2009
Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients - December 01, 2009
Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial - January 01, 2010
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009 - January 01, 2010
A diagnostic algorithm for persistence of very early inflammatory arthritis: the utility of power Doppler ultrasound when added to conventional assessment tools - February 01, 2010
Mesenchymal stem cells in rheumatoid synovium: enumeration and functional assessment in relation to synovial inflammation level - February 01, 2010
Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy - February 01, 2010
The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis - March 01, 2010
Evidence for treating rheumatoid arthritis to target: results of a systematic literature search - April 01, 2010
Treating rheumatoid arthritis to target: recommendations of an international task force - April 01, 2010
PADI4 genotype is not associated with rheumatoid arthritis in a large UK Caucasian population - April 01, 2010
Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial) - March 01, 2010
The fatty Romanus lesion: a non-inflammatory spinal MRI lesion specific for axial spondyloarthropathy - May 01, 2010
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs - June 01, 2010
Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment - June 01, 2010
Dissection of the FCGR3A association with RA: increased association in men and with autoantibody positive disease - June 01, 2010
Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate - June 01, 2010
Bone loss in very early inflammatory back pain in undifferentiated spondyloarthropathy: a 1-year observational study - July 01, 2010
Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008 - March 01, 2010
No evidence for association of the KLF12 gene with rheumatoid arthritis in a large UK cohort - July 01, 2010
Confirmation of association of the REL locus with rheumatoid arthritis susceptibility in the UK population - August 01, 2010
Association of CD40 with rheumatoid arthritis confirmed in a large UK case-control study - May 01, 2010
Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? - September 01, 2010
Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis - November 01, 2010
Beneficial effect of 1-year etanercept treatment on the lipid profile in responding patients with rheumatoid arthritis: the ETRA study - November 01, 2010
Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register - June 01, 2010
The development of the L-QoL: a quality-of-life instrument specific to systemic lupus erythematosus - February 01, 2009
Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA - June 01, 2010
PDF
Miscellaneous
Corrections
Corrections
Free
Compose a Response to This Article
Compose Response
Title
*
Contents
More information about text formats
Plain text
No HTML tags allowed.
Web page addresses and e-mail addresses turn into links automatically.
Lines and paragraphs break automatically.
Author Information
Contributors
First Name and Middle Initial
*
First or given name, e.g. 'Peter'.
Last Name
*
Your last, or family, name, e.g. 'MacMoody'.
Email Address
*
Your email address, e.g. higgs-boson@gmail.com
Occupation
*
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Affiliation
*
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests
Competing interests?
*
Yes
No
Please describe the competing interests
PLEASE NOTE:
A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about
rapid responses.
We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
By submitting this rapid response you are agreeing to our
terms and conditions
for rapid responses and understand that your personal data will be processed in accordance with those terms and our
privacy notice.
I agree to and have read the
terms and conditions
for rapid responses and BMJ
Privacy Notice
*
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Vertical Tabs
Other responses
No responses have been published for this article.
Read the full text or download the PDF:
Subscribe
Log in
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?